Floatz Rating
C38/100
Confidence
Indicative
Sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04864821CT.gov Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Targeting Cd276 Car T Cells (this asset) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early P1 | C · 38 |
| (+)-Vincristine | Milton S. Hershey Medical Center | P2 | BB |
| Ipilimumab | Children's National Research Institute | P2 | BB |
| Olaparib | Fundación de investigación HM | P2 | BB |
| Etoposide | Eisai Limited | P2 | B |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| Irinotecan | Milton S. Hershey Medical Center | P2 | B |
| Cixutumumab | National Cancer Institute (NCI) | P2 | B |
+42 more in the Osteosarcoma cohort
Other indications for Targeting Cd276 Car T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroblastoma | — | P1/2 | CCC · 50 |
| Exocrine Pancreatic Carcinoma | — | P1/2 | CCC · 48 |
| Gastric Cancer | — | Early P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Targeting Cd276 Car T Cells in Osteosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/targeting-cd276-car-t-cells-osteosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →